Briumvi quarterly prescription trends (TRx and NBRx data from IQVIA) and market share gains in relapsing MS segment
Payer coverage decisions and formulary positioning relative to Ocrevus, Kesimpta, and Tysabri
Clinical data readouts or label expansion opportunities (e.g., primary progressive MS, neuromyelitis optica spectrum disorder)
Quarterly revenue beats/misses relative to Street estimates and guidance updates
low - Multiple sclerosis is a chronic, progressive disease requiring continuous treatment regardless of economic conditions. Patients typically maintain therapy through economic cycles due to disease severity and insurance coverage. However, moderate sensitivity exists through employment-linked commercial insurance coverage and potential delays in diagnosis/treatment initiation during severe recessions. Government programs (Medicare/Medicaid) provide ~30-40% of revenue base with more stable demand.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for growth biotech stocks, particularly impacting companies trading on forward earnings; (2) Increased financing costs if the company needs to raise debt or dilutive equity for pipeline development or working capital, though current balance sheet appears adequate with 3.82x current ratio and minimal debt (0.42 D/E). Rate impacts are primarily valuation-driven rather than operational.
Biosimilar competition emerging for anti-CD20 class as Ocrevus patents expire (2027-2029 timeframe), potentially compressing pricing across the category by 30-50%
Shift toward oral disease-modifying therapies or higher-efficacy BTK inhibitors in development that could reduce infused therapy market share
Medicare drug price negotiation provisions under IRA could impact pricing power post-2029 if Briumvi becomes eligible for negotiation
growth - Attracts growth investors focused on commercial-stage biotech with single-product revenue inflection. The 40.8% revenue growth and transition to profitability appeal to investors seeking exposure to MS market expansion without large-cap pharma diversification. High ROE of 133.2% and improving margins attract momentum investors, while negative FCF and high valuation multiples (8.7x P/S) deter value investors. Institutional biotech specialists and healthcare-focused funds comprise core holder base.
No analyst coverage available for this stock.
Trend
+11.8% vs SMA 50 · +1.5% vs SMA 200
Momentum
Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
TGTX News
Unable to load news
About
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
TGTX◀ | $33.83 | +0.15% | $5.4B | 10.8 | +8731.9% | 7256.0% | 1500 |
| $68.56 | -3.59% | $13.3B | — | +12626.1% | -14525.8% | 1500 | |
| $513.72 | -0.71% | $11.8B | — | +43205.3% | -3008.0% | 1500 | |
| $87.60 | +0.60% | $11.5B | — | +3288.2% | -4239.0% | 1500 | |
| $183.72 | -1.59% | $10.7B | 29.2 | +1871.5% | 680.1% | 1500 | |
| $206.53 | -0.59% | $10.6B | — | +6554.5% | -2868.8% | 1500 | |
| $74.81 | +1.81% | $10.5B | 51.8 | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -0.56% | — | 30.6 | +343156.1% | -2389.3% | 1500 |